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Abstract: While cancer has been long recognized as a disease of the genome, the importance of
epigenetic mechanisms in neoplasia was acknowledged more recently. The most active epigenetic
marks are DNA methylation and histone protein modifications and they are involved in basic
biological phenomena in every cell. Their role in tumorigenesis is stressed by recent unbiased
large-scale studies providing evidence that several epigenetic modifiers are recurrently mutated or
frequently dysregulated in multiple cancers. The interest in epigenetic marks is especially due to the
fact that they are potentially reversible and thus druggable. In B-cell progenitor acute lymphoblastic
leukemia (BCP-ALL) there is a relative paucity of reports on the role of histone protein modifications
(acetylation, methylation, phosphorylation) as compared to acute myeloid leukemia, T-cell ALL,
or other hematologic cancers, and in this setting chromatin modifications are relatively less well
studied and reviewed than DNA methylation. In this paper, we discuss the biomarker associations
and evidence for a driver role of dysregulated global and loci-specific histone marks, as well
as mutations in epigenetic modifiers in BCP-ALL. Examples of chromatin modifiers recurrently
mutated/disrupted in BCP-ALL and associated with disease outcomes include MLL1, CREBBP,
NSD2, and SETD2. Altered histone marks and histone modifiers and readers may play a particular
role in disease chemoresistance and relapse. We also suggest that epigenetic regulation of B-cell
differentiation may have parallel roles in leukemogenesis.
Keywords: acute lymphoblastic leukemia; B lymphocytes; histone modifications; chromatin modifiers
1. Introduction
1.1. Acute Lymphoblastic Leukemia in Children
Acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood, and the
majority of cases are classified as B-cell progenitor acute lymphoblastic leukemia (BCP-ALL).
With current therapeutics, the cure rates exceed 80% but the treatment of relapsed or drug-resistant
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disease, and some molecular subtypes, remains challenging. With this high survival, there is little
room for further improvement of outcomes based on escalation of the treatment intensity without
unacceptable toxicity. Rather, the current effort is aimed at proper patient stratification and defining
targetable genetic lesions that would allow for personalized therapy [1–7]. Here, we discuss the data
on altered histone marks in B-cell progenitor acute lymphoblastic leukemia in children. Studying
histone marks may not only help to understand BCP-ALL pathobiology but could identify prognostic
biomarkers or provide rationale for novel therapeutic strategies. There are several agents, including
FDA-approved drugs, aimed at dysregulated epigenetic states at different stages of development,
and these can potentially enhance current therapeutic programs, as shown in preclinical models [8–11].
The aim of this review is to promote research into chromatin modification in BCP-ALL to facilitate
future therapeutic interventions. It is not clear whether the apparent discrepancy between ALL,
with relatively few data on histone modifiers, and acute myeloid leukemia (AML), in which most
patients are reported to have mutations in epigenetic modifiers including in particular DNMT3A
(DNA methyltransferase 3A), TET2 methylcytosine hydroxylase (Ten-Elevan-Translocation-2) or MLL1
(mixed lineage leukemia 1), is truly related to disease biology or a result of study bias [12–14]. The fact
that a large number of studies used cytosine methylation profiling to classify BCP-ALL with prognostic
significance is likely related to the relative ease of DNA methylation studying as compared to histone
modifications [15–24]. There also appear to be more reports on the role of histone modifications and
histone-modifying or chromatin-readers genes in T-cell ALL (with prominent reports on DNMT3A,
TET1, EZH2 (enhancer of zeste 2 polycomb repressive complex 2), SUZ12 (SUZ12 polycomb repressive
complex 2 subunit), MLL2, SETD2 (SET domain containing 2), PHF6 (PHD finger protein 6) and BRD4
(bromodomain containing 4)), despite its relatively low frequency, than in BCP-ALL, and there is little
overlap between the T-cell ALL and BCP-ALL data [25–30].
1.2. Histone Modifications
The traditional view of histones was that they are highly conserved proteins that provide the
packaging of our genome. Now it is recognized that histone proteins have crucial roles in the interaction
between effector proteins and DNA, and are themselves regulated by a number of modifications
imposed by specialized sets of proteins creating an intricate interplay [31–33]. Some of these signatures
appear relatively stable, others appear highly dynamic or might be subject to microenvironmental
metabolic influences [32–35]. The number of recognized posttranslational, covalent histone protein
modification is constantly growing. It is now apparent that they are involved in all basic cellular
phenomena and in particular gene expression regulation, replication, and DNA repair [33,34].
Despite the introduction of high-throughput, genome-wide profiling methods combining chromatin
immunoprecipitation with next-generation sequencing (ChIP-Seq) the data on the significance of
such newly recognized marks in human diseases lag behind biochemical data from model organisms,
though this is partly due to the relatively large quantities of input material required. The global
and loci-specific level of each histone modification is the net result of the action of enzymes that can
introduce the particular covalent modification (“writers”) or remove the mark (“erasers”), some of
which also have non-histone targets. Apart from genomic location, the biological consequences of the
histone marks are related to the action of proteins that interact with modified histones (“readers”) or
recruit further molecules. The term “histone crosstalk” relates to the combinatorial, interdependent,
and context-dependent effects of various histone modifications on the state and interpretation of other
histone modifications [31–34,36–38]. While it was long known that several cancers are associated with
dysregulated levels of several histone modifications, more recent, unbiased genome-wide studies
reported that genes encoding chromatin modifiers and readers are among the most frequently mutated
genes in cancer, providing strong evidence for their role in tumorigenesis [9,39–45].
In this review, we focus on three important and extensively described histone protein
modifications: histone lysine acetylation, histone lysine methylation, and histone phosphorylation.
For each of these major marks we discuss, if available in the literature, the correlative data related
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to their global or loci-specific levels; important data from pre-clinical models; and evidence of
dysregulation of their writers, erasers, and readers in BCP-ALL. The data on other chromatin marks in
BCP-ALL are very scarce as are data on their combinatorial effects (histone crosstalk).
1.3. Histone Lysine Acetylation
The N-acetylation of lysine residues in histone proteins may be considered the most important,
or at least most extensively documented, of all histone marks. Histone acetylation is involved in gene
transcription, chromatin structure, and DNA repair, which are basic cellular phenomena in physiology
and in cancer [33,34,43,46]. Histone acetylation is the net result of the activities of histone lysine
acetyltransferases (KATs) and histone deacetylases (HDACs) [33,36,38].
1.3.1. Mutations/Rearrangements in Genes Involved in Histone Lysine Acetylation
CREBBP is a histone acetyltransferase that can acetylate various residues in several histones,
and in particular H3K18 [33,38]. Recent unbiased, large-scale studies identify recurrent mutations in
CREBBP in multiple cancers including bladder [42], salivary gland [47], esophageal [41], small-cell
and non-small cell lung cancers [39,48], medulloblastoma [45], and lymphoid neoplasia [49–62]. In the
setting of BCP-ALL CREBBP mutations (within the Histone acetyltransferases (HAT) domain) or
deletions were shown to be very common in relapsed cases (18.3% of patients). These lesions were
both acquired at relapse or already present at diagnosis, sometimes in subclones, suggesting a role
in resistance to chemotherapy. Functional experiments suggested this is due to loss of HAT activity
and transcriptional dysregulation [50]. Similar frequency of CREBBP gene mutations in relapsed
cases was reported in a study by Mar et al. [60], and further studies demonstrated that CREBBP
mutation are particularly prevalent in high hyperdiploid ALL [55,57,59]. However, despite the genetic
evidence, we are far from understanding the role of CREBBP in tumorigenesis considering relatively
low incidence of lymphoid neoplasia in Rubinstein-Taybi syndrome that is caused by CREBBP gene
germline defects, and animal models of CREBBP loss that demonstrate hematologic abnormalities but
not leukemia [63].
The role of CREBBP homolog, EP300, is less well established [50] however EP300-ZNF384 was
recently reported as a recurrent gene fusion in BCP-ALL [64].
The role of CREBBP and EP300 in BCP-ALL and in lymphoid neoplasia is further complicated
by the fact that they both contain bromodomains that recognize and bind to acetylated histones,
thus also functioning as chromatin “readers” and recruiting other proteins to chromatin [65]. Inhibitors
of CREBBP/EP300 bromodomains show promising pre-clinical activity in models of leukemia
characterized by the presence of translocations leading to the presence of fusion proteins containing
such bromodomains [66,67]. Several inhibitors of other bromodomains also showed therapeutic
activity in BCP-ALL preclinical models, however it is difficult to conclude which mechanisms, and in
particular which bromodomain-chromatin interactions and downstream effects, are critical for the
effect. Nonetheless, these studies provide evidence for the potential of therapies targeting chromatin
complexes in BCP-ALL [68,69]. Surprisingly, we identified no studies that examined the levels of
CREBBP and other HATs expression in BCP-ALL.
1.3.2. Differential Expression of Genes Involved in Histone Lysine Deacetylation
Several HDACs were demonstrated to be expressed in ALL at the higher levels than in normal
bone marrow cells (HDAC2, -3, -6, -7, -8) and HDAC7 and -9 expression above median was associated
with poor survival [70]. Another study reported overexpression of HDAC1, -2, -8 in ALL and that
HDAC1, -2, 4, -11 expression is associated with unfavourable prognostic factors including poor
prednisone response [71]. There is disappointingly little overlap between the studies, however it
should be pointed out that both B- and T-cell ALL samples were included and their transcriptional
profiles differ profoundly.
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Important study by Sonnemann et al. [72] demonstrated that leukemic cells from ALL patients
are characterized by increased histone deacetylase activity as compared to normal bone marrow cells
using an enzymatic assay, which is a more direct and convincing proof of oncogenic hypoacetylation
in cancer than association studies of HDACs expression. It would be interesting to see how this global
HDAC activity level correlates with survival, or clinical/molecular data such as mutations in HAT
genes, in a larger population of patients. In conclusion, the role for HDAC proteins in BCP-ALL is
less well documented than that of some histone acetyltransferases. Various HDACs, Sir2 proteins
(sirtuins) and histone acetyltransferases are differentially expressed in BCP-ALL molecular subtypes
when publically available microarray datasets are analysed, data not shown. Despite a relative lack
of clinicopathological data on their relevance, there are numerous in vitro and xenograft studies on
the role of HDAC inhibitors in ALL, recently reviewed by Mummery et al. [73]. The most significant
is the study of LBH589, a class I-II HDAC inhibitor, that demonstrated increased survival of human
xenograft-implanted mice and synergy of LBH589 with vincristine and dexamethasone, accompanied
by an increase in histone H3 and H4 acetylation in leukemic cells [74].
1.3.3. The Association of Global and Loci-Specific Levels of Histone Acetylation
A rRecent study from our group confirmed and extended previous finding from adult ALL
patients that associated loss of global Lys-4,-8,-12,-16-histone H4 acetylation with poor outcomes in
pediatric BCP-ALL. Additionally, we demonstrated that in BCP-ALL relatively preserved level of
histone H4 acetylation is linked with the presence of ETV6-RUNX1 gene fusion, PAX5 deletions, and
deletions in genes related B-cell differentiation [75–77]. A study by Bachmann et al. [78] demonstrated
that loss of histone H3 acetylation (H3K9Ac) at BIM locus is associated with glucocorticoid resistance
in xenograft models and in primary patient samples.
1.4. Histone Lysine Methylation
Histone lysine methylation is another of the major histone marks. Methylation of various
lysine residues of histone proteins is the net result of the activities of histone lysine methylases and
demethylases. Histone lysine methylation is mainly associated with chromatin state and transcriptional
regulation [10,33,38].
There are no reports on the role of histone arginine methylation in BCP-ALL.
Mutations/Rearrangements in Genes Involved in Histone Lysine Methylation
Several histone methyltransferases are implicated in BCP-ALL pathogenesis, including MLL1.
Mixed lineage leukemia (MLL1, recently known as KMT2A) translocations are found in around 70%
of infant leukemia and 5% of BCP-ALL. MLL1 is a member of SET domain-containing histone lysine
methyltransferases that also contain EZH2, NSD1, and SET7/9, which are also frequently disrupted
in hematologic neoplasia [79–81]. In BCP-ALL t(11q23) MLL1 gene translocations (best described
MLL1-AF4) are associated with high risk disease and are an established cytogenetic risk factor for
a few decades [81,82]. MLL1/KMT2A is one of the most frequently mutated genes in cancer [83]. MLL1
is a H3K4 methyltransferase and this activity is dependent on its SET domain. H3K4 methylation
is typically associated with transcriptional activation and euchromatin [33,38]. The role of MLL1
fusion oncoproteins in leukemogenesis is believed to be related to overexpression of target genes,
such as HOXA homeobox gene cluster that are normally tightly regulated in hematopoietic progenitors,
due to aberrant histone H3 methylation. However, it is not clear to what extent the role of MLL1
in leukemagenesis is related to its wild-type methyltransferase activity and what is the role of the
particular fusion partners, of which more than 50 were characterized, especially that SET domain
is frequently lost in resulting fusion proteins. It must be also noted that, similarly to CREBBP,
MLL1 contains a bromodomain that provides a potential platform for interaction with various
chromatin complexes [80,81]. This is further complicated by the fact that several MLL1 fusion partners
interact with and recruit DOT1L methyltransferase, specific for H3K79 (which is also associated with
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transcriptional activation). Whatever the exact mechanism, MLL1 lesions are believed to be associated
with aberrant histone methylation and overexpression of target genes. Interestingly, more recent studies
suggest that H3K79met patterns are more consistently associated with MLL1-rearranged leukemia
than H3K4met profiles, and DOT1L is essential for MLL1-driven leukemogenesis as a member of
MLL1-associated multiprotein complexes. Importantly, DOT1L inhibitors may be selectively active
against MLL-rearranged cells (including both AF9 and AF4 fusion partners) [79–81,84–88]. Several
other approaches, apart from DOT1L inhibition, are surveyed in the setting of MLL-rearranged
leukemia, and another member of the multiprotein complex associated with MLL1 that could be
targeted in ALL is WD repeat 5 (WDR5), however this was not studied in pediatric populations or
disease models [89]. A therapeutic potential and antileukemic activity was recently demonstrated
in a study of the MM-401 compound targeting MLL1/KMT2A H3K4 methyltransferase activity in
mixed lineage leukemia, suggesting that wild type MLL1 is necessary for MLL1-rearrangement driven
leukemia [90]. As MLL1-driven leukemia is also associated with aberrant DNA methylation patterns,
another suggested therapeutic strategy is using hypomethylating agents [81]. Similarly, HDAC
inhibitors are also evaluated in this setting based on the assumption that histone methylation pattern
is read in the context of other chromatin marks [81].
Other histone methyltransferases implicated in BCP-ALL leukemagenesis and this include NSD2,
SETD2, and EZH2.
NSD2 (nuclear receptor-binding SET domain protein 2) histone lysine methyltransferase is
responsible for mono- and dimethylation of H3K36. A specific E1099K mutation in NSD2 gene
increased H3K36 dimethylation in several ALL cell lines and xenograft studies. Further, the E1099K
variant was shown to be a frequent feature of BCP-ALL with ETV6-RUNX1 fusion gene [91].
The recurrent character of NSD2 gene mutations in BCP-ALL was confirmed by Huether et al. [44]
and Oyer et al. [92]. H3K36 is normally unmethylated, but it remains to be established how this
gain in methylation contributes to leukemogenesis. It was suggested that it might be due to global
transcriptional dysregulation caused by concomitant decrease in H3K27me3 [92].
SETD2 is an another H3K36 methyltransferase whose mutations are reported in BCP-ALL at
a relatively high frequency (12% of the entire cohort). The frequency of SETD2 gene mutations is increased in
MLL1- and ETV6-RUNX1 rearranged cases and is also increased at relapse [60]. In AML SETD2 defects
are associated with a global loss of H3K36 trimethylation, but this was not studied in BCP-ALL [93].
A recent study by Schafer et al. [94] found a relatively low frequency (1.3%) of mutation in
another histone methyltransferase EZH2 in ALL, similar to low EZH2 mutation prevalence in ALL
seen previously [50]. EZH2 gene mutations might be enriched in hypodiploid ALL [95].
Histone lysine demethylases have been strongly implicated in T-cell acute lymphoblastic
leukemia [30,96], but there is a lack of studies reporting on their alterations in BCP-ALL.
We identified no studies involving pediatric BCP-ALL patients documenting differential
expression of genes involved in histone lysine methylation, the associations of global levels of histone
methylation, or the associations of loci-specific patterns of histone methylation. However, interestingly,
in an in vitro model, loss of IKAROS (IKZF1), that is one of the main drivers of high-risk leukemia and
whose activity restoration is attempted in preclinical models, was associated with decreased level of
global H3K4 methylation [97,98].
1.5. Histone Phosphorylation
Histone phosphorylation plays a major regulatory role in transcription, chromatin condensation,
mitosis, apoptosis, and DNA replication. This is a highly dynamic chromatin modification controlled
by several protein kinases and phosphatases [10,33,38].
Histone Phosphorylation in BCP-ALL
Aberrant phosphorylation of several histone proteins and mutations in genes encoding for
proteins involved in histone phosphorylation are reported in multiple cancers [10]. There is a lack
Cancers 2017, 9, 2 6 of 14
of such reports in the setting of acute lymphoblastic leukemia, which may represent true biological
features of the disease or be related to the fact that ALL is relatively understudied. Still, it is highly
likely that other histone marks are “read” in the context of phosphorylation of residues in the vicinity
and the so far scarce data on histone phosphorylation in BCP-ALL are necessary to fully interpret
other chromatin marks. The notable exception is Janus kinase (JAK2, JAK3), which is a site of recurrent
rearrangements in ALL that are of biological and clinical significance [99,100]. JAK2 was recently
reported to be able to phosphorylate histone H3 at tyrosine 41 (H3Y41), which leads to dissociation
of some effector proteins from chromatin, and global H3Y41 levels are elevated in cell lines with
constitutively active JAK2 [101]. To the best of our knowledge, this role of JAK2 was not studied in the
setting of acute lymphoblastic leukemia. Importantly JAK proteins can be effectively targeted with
ruxolitinib [100,102] and in preclinical models with HSP90 (heat shock protein 90 kDa) inhibitors [103].
Other than that, we are not aware of studies reporting on mutations/rearrangements or differential
expression in genes involved in histone phosphorylation, nor on the associations of global levels or
loci-specific levels of histone phosphorylation. Similarly, several further histone marks are known and
were shown to play role in basic cellular phenomena but no data on their role in BCP-ALL exists.
1.6. Histone Gene Disruption in BCP-ALL
Histone genes themselves may be targets in tumorigenesis. Mullighan et al. [95] demonstrated
8.1% frequency of 6p22 deletions in a histone cluster region in BCP-ALL. This deletion may be enriched
in cases with Down syndrome and hypodiploidy. Loudin et al. [104] reported deletion in a histone
gene cluster at 6p22 in 22% of Down-syndrome ALL patients, and in 3.1% patients without Down
syndrome, and gene expression analysis confirmed lower expression of several histone genes in cases
with homozygous deletions. The same study reports a few likely functional histone genes mutations
in the Down-syndrome patients without those 6p22 deletions. More recently, Holmfeldt [105] reported
a relatively high frequency of histone cluster deletion (19.1%) in hypodiploid ALL. There are no data
on the prognostic significance of these alterations.
1.7. The Evidence for the Role of Histone Modification in B-Cell Differentiation
Another reason to expect a role for histone marks in BCP-ALL leukemagenesis is their involvement
in normal B-cell development, as corrupted developmental regulation frequently plays a role in cancer,
including leukemia [106–109]. Apart from the fact that various epigenetic events likely regulate
all stages of B-cell progenitor development [110], in the context of B-cell differentiation histone
marks were particularly implicated in the regulation of V(D)J rearrangement at immunoglobulin loci.
It was demonstrated that RAG (recombination-activating genes) recombinases specifically recognize
H3K4me3, and loss of this recognition in laboratory models or in patients with immunodeficiency
is related to severely impaired V(D)J recombination [111–115]. The activity and localization
of recombination complexes is also regulated by histone acetylation [116–118]. Aberrant RAG
recombinase activity was recently strongly implicated in BCP-ALL leukemogenesis in several
reports [119–121] and it might be expected that aberrant histone methylation and acetylation marks
play a role in illegitimate or excessive recombination.
2. Conclusions
Recent large unbiased studies provided strong evidence for the role of factors involved in
histone modifications in B-cell progenitor leukemogenesis, and their association with chemoresistance
and relapse. Table 1 summarizes the evidence on the recurrent character of the lesions in genes
encoding histone mark writers and erasers, whereas Figure 1 summarizes the data presented here on
aberrant histone marks and related mutations in chromatin modifiers. Still, the area appears relatively
understudied when compared to other cancers, including hematologic neoplasia. This gap must
be filled to enable novel and targeted therapeutic interventions. Drugs targeting histone modifiers
and readers are entering clinical trials (completed or active clinical trials of such agents in pediatric
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BCP-ALL are presented in Table 2), and are expected to play a role in multidrug regimens combined
with ‘traditional’ cytotoxics. Their use may prove beneficial in unselected BCP-ALL cases irrespective
of molecular build-up but we hope that their future use will be guided by data on genomic and
epigenomic lesions in a particular patient to achieve maximal clinical benefit with minimal toxicities.
Table 1. Mutations/rearrangements of histone writers and erasers in B-cell progenitor acute
lymphoblastic leukemia (BCP-ALL).
Gene (Reference) Histone-Modifying Function Frequency of Mutations/Rearrangements in BCP-ALL Subgroups Enriched
CREBBP [50,51,53,55,57] H3K18 acetyltransferase(and other H3/H4 residues)
Rare in cases without hyperdiploidy
and relapse Relapse, hyperdiploidy
EP300 [50,55] H3K18 acetyltransferase(and other H3/H4 residues) <1% -
MLL1 [3,5,6,82,122,123] H3K4 methyltransferase 5% -
NSD2 [44,91] H3K36 methyltransferase Not documented in unselected patients,up to 14% in subgroups ETV6-RUNX1-rearranged
SETD2 [44,60,93,124] H3K36 methyltransferase 12% MLL- and ETV6-RUNX1-rearrangements, relapse
EZH2 [44,55,94] H3K4 methyltransferase 1.3% hypodiploidy
JAK2 [99,100,125,126] H3Y41 phosphorylase Not determined in unselected patients,up to 10% in high risk disease
BCR-ABL1-like, Down
syndrome, high-risk disease
Table 2. Active and completed clinical trials of drugs potentially targeting histone mark writers and
erasers in pediatric BCP-ALL (as accessed on 25 October 2016, at www.clinicaltrails.gov).
Study
Identifier
Start
Year
Drug Targeting (or Potentially
Targeting) Histone Modifications ALL Population Phase Status
NCT00053963 2002 FR901228 (HDACi) Refractory disease (0–21 years) 1 completed
NCT00217412 2005 Vorinostat (HDACi) Relapsed or refractory disease (1–21 years) 1 completed
NCT00882206 2009 Vorinostat (HDACi) Relapsed or refractory disease (2–60 years) 2 completed
NCT01251965 2010 Ruxolitinib (JAK1/JAK2 inhibitor) Relapsed or refractory disease (14 years or older) 1/2 completed
NCT01321346 2011 Panobinostat (HDACi) Refractory disease (8–21 years) 1 completed
NCT02141828 2014 EPZ-5676 (DOT1L blocker) Relapsed or refractory disease (0–18 years)MLL-rearranged 1 completed
NCT02419755 2015 Vorinostat (HDACi) Relapsed or refractory disease (0–21 years)MLL-rearranged 2 recruiting
NCT02420717 2015 Ruxolitinib (JAK1/JAK2 inhibitor) Ph-like (10 years or older) 2 recruiting
NCT02723994 2016 Ruxolitinib (JAK1/JAK2 inhibitor) CRLF2-rearranged and/or JAK Pathway-mutant(1–21 years) 2 recruiting
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